Mounjaro® (tirzepatide) is a novel diabetes treatment that targets both GIP and GLP-1 receptors, setting a new standard in Type 2 Diabetes care. Approved in 2022, it has shown exceptional results in lowering blood sugar and body weight, outperforming existing treatments like GLP-1 receptor agonists. The SURPASS-4 trial highlighted additional benefits, including reduced mortality. With its dual-action profile and broad therapeutic potential, tirzepatide is poised to reshape the management of metabolic diseases.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Tirzepatide by Stealth Labs, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
